HINT1 protein

A new therapeutic target to enhance opioid antinociception and block mechanical allodynia

Javier Garzón, Raquel Herrero-Labrador, María Rodríguez-Muñoz, Rachit Shah, Ana Vicente-Sánchez, Carston R. Wagner, Pilar Sánchez-Blázquez

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

In the nervous system, the glutamate N-methyl-D-aspartate receptor (NMDAR) restricts the activity of the mu-opioid receptor (MOR). Both receptors are present in midbrain periaqueductal grey (PAG) neurons, an area that plays a central role in the supraspinal antinociceptive effects of opioids. The cross-talk that occurs between these receptors is sustained by the MOR-associated histidine triad nucleotide binding protein 1 (HINT1), which displays nucleoside phosphoramidase and acyl-AMP hydrolase activity. Here we report that the inhibitor of HINT1 enzymatic activity guanosine-5′-tryptamine carbamate (TpGc) significantly enhanced morphine antinociception while preventing the development of tolerance. At the molecular level, TpGc reduced the capacity of MORs to recruit NMDAR activity to negatively regulate opioid signaling. In mice suffering from chronic constriction injury concurrent with increased NMDAR activity, a single intracerebroventricular administration of TpGc attenuated NMDAR function and alleviated mechanical allodynia for several days. These data suggest a potential therapeutic role for HINT1 inhibitors in the clinical management of acute and neuropathic pain.

Original languageEnglish (US)
Pages (from-to)412-423
Number of pages12
JournalNeuropharmacology
Volume89
DOIs
StatePublished - Jan 1 2015

Fingerprint

Hyperalgesia
Staphylococcal Protein A
N-Methyl-D-Aspartate Receptors
Opioid Analgesics
mu Opioid Receptor
Periaqueductal Gray
Carbamates
Guanosine
Acute Pain
Neuralgia
Hydrolases
Adenosine Monophosphate
Therapeutics
Mesencephalon
Nucleosides
Histidine
Constriction
Morphine
Nervous System
Glutamic Acid

Keywords

  • Antinociception
  • Glutamate N-methyl-D-aspartate receptor
  • Guanosine-5′-tryptamine carbamate
  • Histidine triad nucleotide binding protein 1
  • Mu-opioid receptor
  • PKCγ
  • Receptor desensitization

Cite this

Garzón, J., Herrero-Labrador, R., Rodríguez-Muñoz, M., Shah, R., Vicente-Sánchez, A., Wagner, C. R., & Sánchez-Blázquez, P. (2015). HINT1 protein: A new therapeutic target to enhance opioid antinociception and block mechanical allodynia. Neuropharmacology, 89, 412-423. https://doi.org/10.1016/j.neuropharm.2014.10.022

HINT1 protein : A new therapeutic target to enhance opioid antinociception and block mechanical allodynia. / Garzón, Javier; Herrero-Labrador, Raquel; Rodríguez-Muñoz, María; Shah, Rachit; Vicente-Sánchez, Ana; Wagner, Carston R.; Sánchez-Blázquez, Pilar.

In: Neuropharmacology, Vol. 89, 01.01.2015, p. 412-423.

Research output: Contribution to journalArticle

Garzón, J, Herrero-Labrador, R, Rodríguez-Muñoz, M, Shah, R, Vicente-Sánchez, A, Wagner, CR & Sánchez-Blázquez, P 2015, 'HINT1 protein: A new therapeutic target to enhance opioid antinociception and block mechanical allodynia', Neuropharmacology, vol. 89, pp. 412-423. https://doi.org/10.1016/j.neuropharm.2014.10.022
Garzón, Javier ; Herrero-Labrador, Raquel ; Rodríguez-Muñoz, María ; Shah, Rachit ; Vicente-Sánchez, Ana ; Wagner, Carston R. ; Sánchez-Blázquez, Pilar. / HINT1 protein : A new therapeutic target to enhance opioid antinociception and block mechanical allodynia. In: Neuropharmacology. 2015 ; Vol. 89. pp. 412-423.
@article{5ff5d989352040cea570ede115f00fe6,
title = "HINT1 protein: A new therapeutic target to enhance opioid antinociception and block mechanical allodynia",
abstract = "In the nervous system, the glutamate N-methyl-D-aspartate receptor (NMDAR) restricts the activity of the mu-opioid receptor (MOR). Both receptors are present in midbrain periaqueductal grey (PAG) neurons, an area that plays a central role in the supraspinal antinociceptive effects of opioids. The cross-talk that occurs between these receptors is sustained by the MOR-associated histidine triad nucleotide binding protein 1 (HINT1), which displays nucleoside phosphoramidase and acyl-AMP hydrolase activity. Here we report that the inhibitor of HINT1 enzymatic activity guanosine-5′-tryptamine carbamate (TpGc) significantly enhanced morphine antinociception while preventing the development of tolerance. At the molecular level, TpGc reduced the capacity of MORs to recruit NMDAR activity to negatively regulate opioid signaling. In mice suffering from chronic constriction injury concurrent with increased NMDAR activity, a single intracerebroventricular administration of TpGc attenuated NMDAR function and alleviated mechanical allodynia for several days. These data suggest a potential therapeutic role for HINT1 inhibitors in the clinical management of acute and neuropathic pain.",
keywords = "Antinociception, Glutamate N-methyl-D-aspartate receptor, Guanosine-5′-tryptamine carbamate, Histidine triad nucleotide binding protein 1, Mu-opioid receptor, PKCγ, Receptor desensitization",
author = "Javier Garz{\'o}n and Raquel Herrero-Labrador and Mar{\'i}a Rodr{\'i}guez-Mu{\~n}oz and Rachit Shah and Ana Vicente-S{\'a}nchez and Wagner, {Carston R.} and Pilar S{\'a}nchez-Bl{\'a}zquez",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.neuropharm.2014.10.022",
language = "English (US)",
volume = "89",
pages = "412--423",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - HINT1 protein

T2 - A new therapeutic target to enhance opioid antinociception and block mechanical allodynia

AU - Garzón, Javier

AU - Herrero-Labrador, Raquel

AU - Rodríguez-Muñoz, María

AU - Shah, Rachit

AU - Vicente-Sánchez, Ana

AU - Wagner, Carston R.

AU - Sánchez-Blázquez, Pilar

PY - 2015/1/1

Y1 - 2015/1/1

N2 - In the nervous system, the glutamate N-methyl-D-aspartate receptor (NMDAR) restricts the activity of the mu-opioid receptor (MOR). Both receptors are present in midbrain periaqueductal grey (PAG) neurons, an area that plays a central role in the supraspinal antinociceptive effects of opioids. The cross-talk that occurs between these receptors is sustained by the MOR-associated histidine triad nucleotide binding protein 1 (HINT1), which displays nucleoside phosphoramidase and acyl-AMP hydrolase activity. Here we report that the inhibitor of HINT1 enzymatic activity guanosine-5′-tryptamine carbamate (TpGc) significantly enhanced morphine antinociception while preventing the development of tolerance. At the molecular level, TpGc reduced the capacity of MORs to recruit NMDAR activity to negatively regulate opioid signaling. In mice suffering from chronic constriction injury concurrent with increased NMDAR activity, a single intracerebroventricular administration of TpGc attenuated NMDAR function and alleviated mechanical allodynia for several days. These data suggest a potential therapeutic role for HINT1 inhibitors in the clinical management of acute and neuropathic pain.

AB - In the nervous system, the glutamate N-methyl-D-aspartate receptor (NMDAR) restricts the activity of the mu-opioid receptor (MOR). Both receptors are present in midbrain periaqueductal grey (PAG) neurons, an area that plays a central role in the supraspinal antinociceptive effects of opioids. The cross-talk that occurs between these receptors is sustained by the MOR-associated histidine triad nucleotide binding protein 1 (HINT1), which displays nucleoside phosphoramidase and acyl-AMP hydrolase activity. Here we report that the inhibitor of HINT1 enzymatic activity guanosine-5′-tryptamine carbamate (TpGc) significantly enhanced morphine antinociception while preventing the development of tolerance. At the molecular level, TpGc reduced the capacity of MORs to recruit NMDAR activity to negatively regulate opioid signaling. In mice suffering from chronic constriction injury concurrent with increased NMDAR activity, a single intracerebroventricular administration of TpGc attenuated NMDAR function and alleviated mechanical allodynia for several days. These data suggest a potential therapeutic role for HINT1 inhibitors in the clinical management of acute and neuropathic pain.

KW - Antinociception

KW - Glutamate N-methyl-D-aspartate receptor

KW - Guanosine-5′-tryptamine carbamate

KW - Histidine triad nucleotide binding protein 1

KW - Mu-opioid receptor

KW - PKCγ

KW - Receptor desensitization

UR - http://www.scopus.com/inward/record.url?scp=84918511513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918511513&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2014.10.022

DO - 10.1016/j.neuropharm.2014.10.022

M3 - Article

VL - 89

SP - 412

EP - 423

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -